While biotechnology shares are not cheap, they are nowhere near "bubble-like" valuations, says Bill Stone, Chief Investment Strategist at PNC Asset Management Group.» Read More
The NYSE Arca Biotech index spacer hit an all-time high Monday, as investors continue to seek out the group for its above average growth prospects.
AstraZeneca has appointed Pascal Soriot, former chief executive of Genentech, as its new chief executive following the departure of David Brennan earlier this year.
Yu-dee Chang, Principal and Chief Advisor at ACE Investment Strategists, says U.S. markets are "very confused" right now and that's why investors are on the sidelines ahead of Ben Bernanke's speech on Friday. He suggests now is not the time to take aggressive positions.
James Foster, Charles River Laboratories CEO, offers insight on his company's quarterly earnings, and how the drug approval process fits in with the FDA's work.
Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.
Investors need to see this as a speculative stock and take some profits as they come in, he said.
In the wake of Friday’s disappointing jobs report, “Mad Money” host Jim Cramer thinks investors need to prepare for the possibility of a recession.
The FMHR traders share their top three trades of the day, including AutoNation reporting a 38 percent increase for vehicle sales in June; and Dennis Gartman of The Garman Letter explains why he thinks the livestock business is facing even tougher times.
With the weight loss market heating up, stocks like Arena Pharmaceuticals may be spelling out a big rally for the drug retail space.
“Mad Money” host Jim Cramer has the answer.
Last week, Celgene announced it was pulling its Revlimid application in Europe, and Mad Money host Jim Cramer explains why he thinks investors should buy into the stock now.
A look at the impact of the Supreme Court's ruling on biotech stocks, with James Greenwood, BIO CEO.
Could Obamacare be a "legacy-killer" for Obama? David Goodfriend, former Clinton White House official, and Michael Medved, radio talk show host, share their opinions.
CNBC's John Harwood reports on the anticipation for the ruling on Obamacare tomorrow; and Edward Klein, Author of "The Amateur," weighs in. "If the Supreme Court rules against Obamacare, I think it will be a grievance blow to [Obama's] presidency," says Klein.
Discussing the impact the ruling of Obamacare could have on the economy, with Senator John Barrasso (R-WY); Ron Kruszewski, Stifel Nicolaus & Company CEO; and Michael Farr, Farr, Miller & Washington.
The biotech sector is up more than 1 percent today, and discussing what investors can expect after tomorrow's health care reform ruling, with ISI's biotech and pharmaceuticals major analyst Mark Schoenebaum. "If tomorrow the whole bill is struck down, technically, earnings and revenue estimates for all of biotech and all of pharma companies are going to go up," says Schoenebaum.
Shares of Arena Pharmaceuticals spiked on news the FDA approved its anti-obesity drug, with the Fast Money traders; and discussing how tomorrow's ruling on the health care reform could impact the biotech sector, with Mark Schoenebaum, ISI.
The "Mad Money" host spoke with the CEO of Seattle Genetics about the safety of the biotech space.
Daniel Junius, CEO of Immunogen, discusses drugs the company is developing.
Investors who jumped into U.S. Treasurys and the dollar during the latest flare-up of the EU crisis appear to have expanded into gold and other metals, according to a new report.